BIOVECTRA appoints Steve Klosk and Gordon Mccauley to its Board of Directors

– CANADA, Charlottetown –  BIOVECTRA, leading Canadian biotech, and pharmaceutical CDMO today announced the appointment of Gordon McCauley and Steven Klosk to its Board of Directors.

Gordon McCauley is President and CEO of adMare BioInnovations, and Steven Klosk is the former CEO of Cambrex Corporation.

“Mr. Klosk and Mr. McCauley are innovative executives who offer a wealth of experience to the BIOVECTRA Board of Directors,” said CEO, Oliver Technow. “BIOVECTRA’s ambitious growth plans will be well-supported through the considerable leadership and expertise that I know each will contribute as directors with our board.”

About Gordon C. McCauley

Gordon McCauley BA, MBA, ICD.D is an accomplished life science executive and investor, having served as president and senior executive of several health care enterprises. As President and CEO of adMare, Mr. McCauley leads its mission to build companies, ecosystems, and talent in the life sciences industry. adMare has over 25 portfolio companies that have attracted more than $1.4 billion of investment with a combined value of over $3 billion.

“I am excited to help as a director with BIOVECTRA,” said Gordon McCauley. “What an excellent example of the type of world-leading companies we can build in Canada. I know BIOVECTRA leadership care deeply about producing high-quality products to better serve patient care. I look forward to helping BIOVECTRA scale new heights.”

About Steven Klosk

Steven Klosk BS, JD is a consummate executive of the life sciences industry with over 25 years of experience in CDMO leadership. Mr. Klosk retired as CEO of Cambrex Corporation in 2020 after leading its sale to Permira, a global private equity firm. During his tenure, Cambrex became a leading global and fully integrated supplier of drug substances, drug products, and testing services across the entire drug life cycle to both the innovator and generic pharmaceutical markets. The company grew to over 2,000 employees spanning a network of 12 manufacturing and research and development sites in North America and Europe.

“I am thrilled to serve on the board of directors of this thriving CDMO which places care for patients, clients, and its team as integral to BIOVECTRA’s success,” commented Steven Klosk. “This is an exciting time in the life sciences industry, and I look forward to working with the board to help BIOVECTRA reach its optimal success.”


BIOVECTRA is a global biotech and pharmaceutical CDMO (contract development and manufacturing organization) that specializes in clinical-to-commercial scale production capabilities for biologics, bioreagents, fermented small molecules, synthetic small molecules, and active pharmaceutical ingredients. Flexibility, creativity, process optimization, and compliance are at the heart of our method. With over 550 employees and cGMP facilities in Prince Edward Island and Nova Scotia, Canada we assure our programs advance on time and with the highest quality outcomes.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.